Science and Research

MTAPESTRY 104: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the MTA-cooperative PRMT5 inhibitor AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other thera-pies in adult participants with metastatic or locally advanced methyl-thioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 adminis-tered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.

Study details
Study-ID: NCT06333951, 2024-511253-21
Study-ID: NCT06333951, 2024-511253-21
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: TLRC
DZL Participating Sites: TLRC
Start Date: 17.09.2024
Completion Date: 27.10.2031
Status: Recruiting
Status: Recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.